Perrigo chief executive and chairman Joe Papa.  Photograph: Brenda Fitzsimons / The Irish Times

Perrigo, the Irish specialist in over the counter drugs, has agreed to buy a portfolio of products from GlaxoSmithKline. GSK’s consumer healthcare div(...)

Robert J. Coury, vice chairman and chief executive officer of Mylan told investors he may sweeten the company’s cash-and-stock offer for  Perrigo, which has rejected Mylan’s most recent offer of $75 in cash and 2.3 Mylan shares for each Perrigo share. (Photograph: Mannie Garcia/Bloomberg News)

Mylan’s chairman told investors he may sweeten the company’s cash-and-stock offer for Irish headquartered Perrigo by adding terms to reduce the risk (...)

Robert J. Coury, vice-chairman and chief executive of Mylan. Photographer: Mannie Garcia/Bloomberg News

Generic drugs group Mylan boosted its cash-and-stock offer to buy Irish company Perrigo to $34.10 billion, but the bid was swiftly rejected.Mylan’s p(...)

Bank of Ireland was the standout stock on the Dublin market on Monday, according to one analyst. The bank’s shares  finished at 36 cent

European shares reversed early losses and closed up yesterday, with persistent concerns about Greece’s debt situation offset by optimism that a reshu(...)

A generic form of the drug Plavix sits on crates at a Mylan Pharmaceuticals distribution centre. The drug maker Mylan has offered to acquire Perrigo for about $29 billion in what would be the latest mega-merger among drug makers if it is completed. Photograph: Travis Dove/The New York Times

It’s been a busy few weeks for US pharma giant Mylan, which reports quarterly earnings today. Firstly, it made a proposal to buy Dublin-based Perrigo,(...)

Twitter: results out tomorrow.  Photographer: Andrew Harrer/Bloomberg
For Your Diary

TODAY Results: Alkermes; Apple; Bankia; Doosan; Jones Lang LaSalle; Mylan. Meeting: Dragon Oil AGM (Intercontinental Hotel, Park Lane, London) Indi(...)

Robert Coury, chief executive of Mylan pharmacutical company. Photograph: Alan Betson / THE IRISH TIMES

Generic drugmaker Mylan says it will take its $31 billion offer for Perrigo directly to shareholders, in what is set to be one of the most high-profil(...)

Joe Papa CEO and president of Perrigo, which has rejected a $29 billion bid from rival Mylan. Photograph: Brenda Fitzsimons / THE IRISH TIMES

Dublin-based Perrigo has rejected a $29 billion bid from generics group Mylan. The company said its board unanimously rejected the $205 per share offe(...)

Teva factory sign on its plant in Jerusalem: Teva says its stock-and-cash offer of $82 a share represented a 48 per cent premium to Mylan’s stock price on March 10th, which it said was the last day of trading prior to the widespread speculation. Photograph: Menahem Kahana

Generic drugmaker Teva Pharmaceutical Industries Ltd yesterday proposed buying Mylan for $40 billion, saying it was a better deal than the smaller riv(...)

An employee collects newly-manufactured pills at the tablet production plant at Teva Pharmaceutical Industries Ltd.’s headquarters in Jerusalem. Photograph: Adam Reynolds/Bloomberg

Generic drugmaker Teva Pharmaceutical Industries said on Tuesday that it had proposed buying rival Mylan for $82.00 per share in a mix of stock and c(...)